C11orf57 Inhibitors
C11orf57 inhibitors are a diverse class of compounds that can affect various cellular signaling pathways and processes. Staurosporine, by inhibiting PKC, could reduce the phosphorylation of proteins that are necessary for the activity or stability of C11orf57, leading to its functional downregulation. Similarly, LY294002 and Wortmannin, both PI3K inhibitors, could decrease the phosphorylation of Akt, which may be required for the optimal functional activity of C11orf57. By reducing PI3K/Akt signaling, these compounds indirectly inhibit the activity of C11orf57.
MEK inhibitors such as U0126 and PD98059 prevent the activation of ERK1/2, which could be essential for the function of C11orf57. The inhibition of these kinases may, therefore, lead to a decrease in C11orf57 activity. Rapamycin's inhibition of mTORC1 affects protein synthesis and other processes that C11orf57 may rely on, indirectly leading to its functional inhibition. In contrast, proteasome inhibitors like Bortezomib and MG132 could lead to the accumulation of negative regulators of C11orf57, inhibiting its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that increases the acetylation of histones, leading to an open chromatin structure and often resulting in increased transcription. However, for genes that are regulated by repressors that are inactivated by acetylation, Trichostatin A can indirectly lead to decreased expression and thus functional inhibition of C11orf57. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A DNA methyltransferase inhibitor that reduces DNA methylation levels. Hypomethylation of promoters can activate the transcription of genes, but for genes like C11orf57, which may be repressed by transcription factors that are sensitive to methylation state, this can lead to a decrease in C11orf57 expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that prevents the degradation of ubiquitin-tagged proteins. While generally increasing protein levels, MG132 can result in the accumulation of regulatory proteins that inhibit the function of C11orf57, thereby indirectly reducing its activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor that can cause the buildup of proteins that negatively regulate C11orf57 function. For instance, if a negative regulator of C11orf57 is normally degraded by the proteasome, bortezomib-induced accumulation of this regulator could inhibit C11orf57 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can lead to reduced AKT phosphorylation and activity. Since PI3K/AKT signaling can regulate a variety of proteins, inhibition of this pathway by LY294002 can lead to the activation of factors that inhibit C11orf57, reducing its functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can decrease the activity of the mTORC1 complex, leading to reduced protein synthesis and cell growth. As C11orf57 function may be related to these cellular processes, rapamycin can indirectly inhibit its function by downregulating the pathways it is involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that prevents ERK phosphorylation and activation. If C11orf57 operates within the MAPK/ERK pathway, U0126 would inhibit upstream signaling, potentially reducing the functional activation of C11orf57. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor like LY294002, wortmannin can lead to reduced PI3K/AKT signaling. This can cause the activation of transcription factors or other regulatory proteins that inhibit C11orf57 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
An inhibitor of p38 MAPK, which reduces the phosphorylation of downstream targets within the MAPK pathway. If C11orf57 is regulated by p38 MAPK activity, SB203580 can lead to its functional inhibition by impeding signaling events that activate C11orf57. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that blocks ERK activation, leading to reduced MAPK pathway signaling. If C11orf57 is associated with the ERK pathway, PD98059 would inhibit its functional activity by blocking upstream signaling events. | ||||||